Zoryve (Roflumilast) Patent Expiration, LOE Window & CMS Spending
Zoryve (Roflumilast) by Arcutis Biotherapeutics: FDA Orange Book LOE 2037-08-25, 9 AB generics, $53.3M 2024 CMS Part D & Medicaid spend, and $965 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Arcutis Biotherapeutics |
| FDA Application & Pathway | N215985 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2037-08-25 |
| Orange Book Patents (*PED Extensions) | 18 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $53.3M |
| 2024 Medicare Part D Spend | $25.6M |
| 2024 Medicaid Spend | $27.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($965 intro WAC) |